Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 1 of 46

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

This slide set is based on a comparative effectiveness review (CER) titled Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA), which was developed by the Duke Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ) under Contract No. 290-2007-10066 -I and is available online at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.

CERs are comprehensive systematic reviews of the literature that usually compare two or more types of treatment, such as different drugs or adding a second drug to usual care for the same disease. The literature included in this review was identified in (1) searches for trials and studies that explicitly evaluated the impact of any disease-modifying antirheumatic drug (DMARD) in children 18 years of age or younger with juvenile idiopathic arthritis (JIA) according to the current definition of the American College of Rheumatology (ACR); (2) trials and studies with a defined comparator; and (3) trials and studies with a duration of at least 3 months. Searches were conducted for studies published prior to December 23, 2010.